3.2 Influence of Policy and Environment on Biochemical Market

3.2.1 Support with Favorable National Policies

In 2019, the State Council successively promulgated three policy documents closely related to the biochemical analysis instruments and reagents, which laid an important policy foundation for the development of biochemical analysis instruments and reagents. The Office of the Central Cyberspace Affairs Commission issued the document on the management of biochemical analysis instruments and reagents, which played an important role in the related industry, and defined the relevant market management policies for the Internet resource collaboration service business regarding the business form of biochemical analysis instruments and reagents. The Ministry of Industry and Information Technology issued the Three-Year Action Plan for the Development of Biochemical Analysis Instruments and Reagents (2019-2021), which proposed the guiding ideology, basic principles, development goals, and key tasks for the development of biochemical analysis instruments and reagents in China. In 2020, the Thirteenth Five-Year Plan for the Development of Biochemical Analysis Instrument and Reagent Industry issued by the central government unequivocally required that the scale of the biochemical analysis instrument and reagent industry would increase by 30% by 2020, and various local governments issued the local policies to increase the penetration rate of the industry.

In the recent 2 years, seven departments including the Ministry of Commerce have jointly formulated the Special Action Plan for the Optimization and Upgrading of Commodity Markets (2021-2025), which explicitly proposes to promote the integration of domestic and foreign trade, and encourages the production and sales activities in the commodity market, and support export products to domestic sales according to the requirements of "same production line, same quality and same standard." Domestic enterprises are encouraged to complete the domestic substitution and sell their products abroad. The Guiding Opinions of the General Office of the State Council on Promoting the Healthy Development of the Pharmaceutical Industry stipulates that if the domestic drugs and medical devices can meet the requirements, domestic products must be procured for the government procurement projects in principle, and the allocation of domestic equipment must be gradually enhanced in public medical institutions.

Last: In Vitro Diagnostic Industry in China - Clinical Chemistry XII

Next: In Vitro Diagnostic Industry in China - Clinical Chemistry XIV